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BACKGROUND: Hypocholesterolemia is a marker of liver disease, and patients with a Fontan circulation may have hypocho-
lesterolemia secondary to Fontan- associated liver disease or inflammation. We investigated circulating lipids in adults with a 
Fontan circulation and assessed the associations with clinical characteristics and adverse events.
METHODS AND RESULTS: We enrolled 164 outpatients with a Fontan circulation, aged ≥18 years, in the Boston Adult Congenital 
Heart Disease Biobank and compared them with 81 healthy controls. The outcome was a combined outcome of nonelective 
cardiovascular hospitalization or death. Participants with a Fontan (median age, 30.3 [interquartile range, 22.8– 34.3 years], 
42% women) had lower total cholesterol (149.0±30.1 mg/dL versus 190.8±41.4 mg/dL, P<0.0001), low- density lipoprotein 
cholesterol (82.5±25.4 mg/dL versus 102.0±34.7 mg/dL, P<0.0001), and high- density lipoprotein cholesterol (42.8±12.2 mg/
dL versus 64.1±16.9 mg/dL, P<0.0001) than controls. In those with a Fontan, high- density lipoprotein cholesterol was inversely 
correlated with body mass index (r=−0.30, P<0.0001), high- sensitivity C- reactive protein (r=−0.27, P=0.0006), and alanine 
aminotransferase (r=−0.18, P=0.02) but not with other liver disease markers. Lower high- density lipoprotein cholesterol was 
independently associated with greater hazard for the combined outcome adjusting for age, sex, body mass index, and func-
tional class (hazard ratio [HR] per decrease of 10 mg/dL, 1.37; 95% CI, 1.04– 1.81 [P=0.03]). This relationship was attenuated 
when log high- sensitivity C- reactive protein was added to the model (HR, 1.26; 95% CI, 0.95– 1.67 [P=0.10]). Total cholesterol, 
low- density lipoprotein cholesterol, and triglycerides were not associated with the combined outcome.
CONCLUSIONS: The Fontan circulation is associated with decreased cholesterol levels, and lower high- density lipoprotein cho-
lesterol is associated with adverse outcomes. This association may be driven by inflammation. Further studies are needed to 
understand the relationship between the severity of Fontan- associated liver disease and lipid metabolism.
Key Words: adult congenital heart disease ■ Fontan ■ high- density lipoprotein cholesterol ■ lipids ■ single ventricle
Patients born with a functional single ventricle typi-cally undergo a series of operations that culminate in a Fontan procedure, which creates a circulation 
where systemic venous blood flows to the pulmonary 
arteries without the benefit of a subpulmonary ventric-
ular pump. This leads to elevated venous pressure, 
constrained systemic ventricular preload, and relatively 
low cardiac output. Long- term sequelae include heart 
failure, arrhythmia, liver fibrosis/cirrhosis, and prema-
ture death. However, predicting which patients are 
at highest risk of adverse outcomes remains difficult. 
Circulating biomarkers that can aid in risk stratifica-
tion would be useful to guide care in this challenging 
population.
Several studies have evaluated circulating bio-
markers in patients with a Fontan circulation.1- 4 
Further biomarker research may aid in better under-
standing the Fontan circulation and, more directly, 
a set of biomarkers representing orthogonal patho-
physiologies may be able to identify patients at risk 
for adverse outcomes. Serum lipid levels are an inex-
pensive, potentially useful biomarker in patients with 
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a Fontan. A prior study including 88 patients, mostly 
in the pediatric age range, reported lower cholesterol 
in those with a Fontan circulation compared with 
healthy controls.5 Since cholesterol is synthesized 
in the liver, decreased total cholesterol, low- density 
lipoprotein cholesterol (LDL- C), and high- density li-
poprotein cholesterol (HDL- C) may be caused by liver 
dysfunction from Fontan- associated liver disease 
(FALD).6 In other chronic liver diseases, hypocho-
lesterolemia indicates more severe liver dysfunction, 
and HDL- C may be the best indicator of the degree 
of liver disease and prognosis.7,8
This study aims to increase our understanding of 
lipid levels, focusing on HDL- C, in patients with a Fontan 
circulation. We compared lipid levels between a rela-
tively large cohort of prospectively enrolled adults with 
a Fontan circulation and a control group. Associations 
between lipid levels, clinical characteristics, and clinical 
outcomes were analyzed. We hypothesized that lipid 
levels would be lower in patients with a Fontan and 
that lower cholesterol levels would be associated with 
an increased risk for adverse cardiac outcomes in pa-
tients with a Fontan circulation.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Sample
We evaluated patients aged ≥18 years with a Fontan 
circulation who were enrolled prospectively in the 
Boston Adult Congenital Heart Disease Biobank 
between March 15, 2012, and May 1, 2019. We ex-
cluded patients with a history of Fontan circulation 
who had subsequently undergone 2- ventricle repair 
or cardiac transplantation before enrollment. We also 
included controls enrolled in the Biobank who were 
aged <61 years, with the age cutoff based on the age 
of the oldest participant with Fontan. Controls were 
nonsmokers without diabetes mellitus or known 
cardiovascular disease who were family/friends of 
patients with congenital heart disease or who were 
recruited using postings on the Boston Children’s 
Hospital website. The study was approved by the 
Boston Children’s Hospital institutional review board, 
and written informed consent was obtained from all 
participants; there was a formal reliance agreement 
between the institutional review boards of Partners 
HealthCare/Brigham and Women’s Hospital and 
Boston Children’s Hospital.
Lipid and Other Laboratory Assessment
Laboratory testing was performed on nonfasting 
samples. Blood was collected in a serum separator 
tube and allowed to clot for 30 to 60 minutes at room 
temperature, followed by centrifugation at 1300 g for 
10  minutes at 4°C. Triglycerides, total cholesterol, 
and HDL- C were measured using an enzymatic, 
colorimetric method (Cholesterol Gen.2, Roche 
Diagnostics) meeting standard goals of ≤3% preci-
sion and bias by a Clinical Laboratory Improvement 
Amendments– approved laboratory (LabCorp, 
Laboratory Corporation of America). LDL- C was cal-
culated using the Friedewald equation. Patients with 
CLINICAL PERSPECTIVE
What is New?
• Adults with a Fontan circulation had lower total 
cholesterol, low- density lipoprotein cholesterol, 
and high- density lipoprotein cholesterol (HDL- C) 
than healthy controls.
• HDL- C in patients with a Fontan was associ-
ated with higher alanine aminotransferase and 
lower albumin but not with other markers of 
liver disease severity, including Model for End- 
stage Liver Disease Excluding INR or VAST 
score (features of portal hypertension: 1 point 
each for varices, ascites, splenomegaly, or 
thrombocytopenia).
• Lower HDL- C was independently associated 
with the composite outcome of nonelective 
cardiovascular hospitalization or death; the re-
lationship between HDL- C and the composite 
outcome was attenuated when adjusting for 
high- sensitivity C- reactive protein.
What are the Clinical Implications?
• Low HDL- C in adults with a Fontan circulation 
is associated with adverse outcomes and this 
may be driven by chronic inflammation.
• Further studies are needed to understand the 
relationship between the severity of Fontan- 
associated liver disease and lipid metabolism.
Nonstandard Abbreviations and Acronyms
FALD Fontan- associated liver disease
MELD Model for End- stage Liver Disease
MELD- XI Model for End- stage Liver Disease 
Excluding INR
VAST Imaging features of portal 
hypertension: 1 point each for 
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markedly elevated triglycerides (>400  mg/dL; n=3 
Fontan, n=1 control) were excluded from analyses 
of LDL- C but were included in other analyses. Non– 
HDL- C was calculated as total cholesterol minus 
HDL- C. hs- CRP (high- sensitivity C- reactive protein) 
was measured from these fresh serum samples using 
a latex particle- enhanced immunoturbidimetric assay 
(Roche Diagnostics) with a lower limit of detection of 
0.1  mg/L and between- run coefficients of variation 
of 3.1% and 2.3% at mean values of 1.5 mg/L and 
11.4 mg/L, respectively. A subset of the blood was 
collected in an EDTA tube and processed to plasma 
by centrifugation at 1300  g for 10 minutes at 4°C, 
and then aliquoted and frozen at −80°C. All measure-
ments were performed on specimens with no prior 
freeze- thaw cycles. NT- proBNP (N- terminal pro- B- 
type natriuretic peptide) was measured in a research 
laboratory using an electrochemiluminescence im-
munoassay (Roche Diagnostics). Other assays were 
performed as previously outlined.9
Clinical and Outcomes Assessment
Demographic, anthropometric, and other clinical 
data, including age at Fontan, type of Fontan, primary 
congenital heart disease diagnosis, and medications 
were extracted from medical records. Imaging and 
laboratory data were used to calculate Model for End- 
stage Liver Disease Excluding INR (MELD- XI)10 and 
VAST (features of portal hypertension: 1 point each 
for varices, ascites, splenomegaly, or thrombocyto-
penia) scores.11 If the presence of a variable for the 
VAST score was not assessed, then it was assumed 
that the patient was negative for that variable. The 
primary outcomes of interest were all- cause mortality 
and a combined outcome of nonelective cardiovas-
cular hospitalization or death. Nonelective cardio-
vascular hospitalization was defined as an overnight 
admission for heart failure, arrhythmia or symptoms 
of arrhythmia, thrombotic or embolic events, cerebral 
hemorrhage, or a specific Fontan- related complica-
tion (ie, ascites, protein- losing enteropathy, plastic 
bronchitis).
Statistical Analysis
Continuous variables are presented as mean±SD for 
normally distributed variables and median (interquar-
tile range) for non- normally distributed variables. We 
also categorized HDL- C according to tertile to assess 
for associations with clinical variables. Unadjusted 
linear regression was used to compare continuous 
variables between 2 groups, while either the chi- 
square or Fisher exact test was used to analyze cat-
egorical variables between groups. Variables with 
heavily skewed distributions (eg, NT- proBNP, hs- 
CRP, and triglycerides) were natural log- transformed. 
Associations between continuous variables were as-
sessed using Pearson product- moment correlation. 
The log- rank test and Cox regression were used to 
perform univariate and multivariable survival analysis, 
respectively. Time- to- event was defined from a time 
origin of the date of biospecimen collection until the 
date of the first clinical event, with censoring of event- 
free individuals at the most recent clinical follow- up 
date when event status was known. Multivariable 
models adjusted for age, sex, body mass index (BMI), 
and New York Heart Association class I versus II and 
higher. The assumption of proportional hazards was 
assessed for each model, and there was no apparent 
violation.
SAS version 9.4 (SAS Institute Inc.) and GraphPad 
Prism (GraphPad Software) were used for analyses. 
A 2- sided P value <0.05 was considered statistically 
significant.
RESULTS
Baseline demographic and clinical data for pa-
tients with a Fontan (n=164) and for controls (n=81) 
are shown in Table 1. Additional baseline char-
acteristics of the Fontan cohort are shown in 
Table 2. Compared with controls, patients with 
a Fontan circulation had 22% lower total choles-
terol (149.0±30.1  mg/dL versus 190.8±41.4  mg/dL, 
P<0.0001; adjusted for age, sex, and BMI), 33% 
lower HDL- C (42.8±12.2 mg/dL versus 64.1±16.9 mg/
dL, P<0.0001), 19% lower LDL- C (82.5±25.4  mg/
dL versus 102.0±34.7  mg/dL, P<0.0001), and 
16% lower non– HDL- C (106.1±32.6  mg/dL versus 
126.7±42.5 mg/dL, P<0.0001) (Figure 1). There was 
no difference in triglyceride level (119.3±85.2 mg/dL 
versus 124.4±84.8  mg/dL, Wilcoxon rank sum test 
P=0.82). Only 4 patients (2.4%) with a Fontan circula-
tion were taking a statin, and those 4 patients had 
similar HDL (37.5±3.9 mg/dL) and slightly higher LDL 
(100±36.7 mg/dL) levels compared with patients with 
a Fontan not taking a statin. One of the 4 patients tak-
ing a statin had heterozygous familial hypercholester-
olemia (HDL=33, LDL=142); excluding this patient did 
not affect the findings substantially. No patient was 
taking a nonstatin lipid medication, and no control 
participant was taking a lipid- lowering medication.
Among the 164 patients with a Fontan circula-
tion, HDL- C inversely correlated with BMI (r=−0.30, 
P<0.0001), LDL- C (r=−0.25, P=0.002), triglycerides 
(r=−0.40, P<0.0001), and hs- CRP (r=−0.27, P=0.0006) 
(Figure 2). HDL- C positively correlated with percent pre-
dicted peak oxygen consumption on cardiopulmonary 
exercise testing (r=0.28, P=0.001). Correlations be-
tween lipid levels, clinical factors, and laboratory values 
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with age at the time of measurement or the duration 
of time since the Fontan procedure; however, female 
sex was significantly associated with higher HDL- C 
(Table 4). HDL- C correlated modestly with alanine ami-
notransferase (r=−0.18, P=0.02) and albumin (r=0.18 
P=0.02). However, there were no other statistically sig-
nificant associations between HDL- C and laboratory 
tests associated with liver disease including aspar-
tate aminotransferase, alkaline phosphatase, platelet 
count, VAST score, or MELD- XI score (Tables 3 and 4).
Outcomes Analysis
The median follow- up duration was 2.8 years (inter-
quartile range, 1.2– 5.5 years). The composite outcome 
of death or nonelective cardiovascular hospitalization 
occurred in 56 patients (34%), including 15 deaths (9%). 
Causes of death included heart failure (n=3, 20%), ar-
rhythmia or sudden death (n=3, 20%), infection (n=2, 
13%), procedural complication (n=1, 7%), hemoptysis 
(n=1, 7%), hepatocellular carcinoma (n=1, 7%), and un-
known (n=4, 27%). Factors associated with the com-
posite outcome are shown in Table S1.
Lower HDL- C was associated with a greater risk of 
the combined outcome of death or nonelective hospi-
talization (unadjusted hazard ratio [HR] per decrease of 
10 mg/dL, 1.30; 95% CI, 1.01– 1.67 [P=0.045], C statis-
tic=0.575). In a multivariable model adjusting for age, 
sex, BMI, and New York Heart Association functional 
class I versus II and higher, HDL- C remained associ-
ated with a greater hazard for the combined outcome 
(HR per decrease of 10  mg/dL, 1.37; 95% CI, 1.04– 
1.81 [P=0.0264], model C statistic=0.690). Adding log 
hs- CRP to the multivariable model attenuated the re-
lationship of HDL- C with the combined outcome (HR 
per decrease of 10  mg/dL, 1.26; 95% CI, 0.95– 1.67 
[P=0.10], model C statistic=0.708). The addition of 
other variables associated with the outcome (Table S1) 
did not attenuate the relationship between HDL- C and 
the composite outcome to the same extent (eg, HR, 
1.35 [95% CI, 1.02– 1.80]; HR, 1.30 [95% CI, 0.98– 1.72]; 
HR, 1.31 [95% CI, 0.99– 1.72]; and HR, 1.38 [95% CI, 
1.03– 1.85] adjusting the model for hemoglobin, albu-
min, VAST score, and log NT- BNP, respectively, rather 
than for log hs- CRP).
In contrast to HDL- C, no other lipid level was as-
sociated with the combined outcome: total cholesterol 
(HR per decrease of 10 mg/dL, 0.95; 95% CI, 0.86– 
1.05 [P=0.88], model C statistic=0.549); LDL- C (HR 
per decrease of 10 mg/dL, 0.91; 95% CI, 0.81– 1.02 
[P=0.10], model C statistic=0.570); and log triglycerides 
(HR, 0.84; 95% CI, 0.50– 1.42 [P=0.52], model C sta-
tistic=0.518). No lipid variable was associated with 
all- cause mortality, although the point estimate of the 
effect size was similar to that observed for the com-
posite outcome (eg, for HDL- C: HR per decrease of 
10  mg/dL, 1.26; 95% CI, 0.78– 2.05 [P=0.339], C 
statistic=0.583).
Table 1. Baseline Demographic and Clinical Data for Patients With a Fontan Circulation and Controls
Fontan (n=164) Controls (n=81) Unadjusted P Value Adjusted P Value
Age, y 30.3 (22.8– 34.4) 34.8 (23.9– 44.4) 0.003 0.002
Female 69 (42) 61 (75) <0.0001 <0.0001
Body mass index, kg/m2 25.2±4.6 24.9±5.3 0.65 0.64
Creatinine, mg/dL 0.87±0.2 0.78±0.1 0.0002 <0.0001
AST, U/L 26.6±9.1 20.6±6.1 <0.0001 <0.0001
ALT, U/L 27.7±12.3 18.5±13.5 <0.0001 <0.0001
Alkaline phosphatase, mg/dL 88.1±30.5 62.5±17.8 <0.0001 <0.0001
Bilirubin, total, mg/dL 1.0±0.9 0.5±0.3 <0.0001 <0.0001
Albumin, gm/dL 4.7±0.5 4.6±0.3 0.31 0.34
Platelet count, K/µL 180±55.1 272±55.4 <0.0001 <0.0001
MELD- XI score 10.6 (9.4– 10.8) 9.4 (9.4– 9.4) <0.0001 <0.0001
hs- CRP, mg/dL 1.3 (0.7– 3.2) 0.6 (0.3– 1.2) 0.09 0.09
Total cholesterol, mg/dL 149.0±30.1 190.8±41.4 <0.0001 <0.0001
LDL- C, mg/dL 82.5±25.4 102.0±34.7 <0.0001 <0.0001
HDL- C, mg/dL 42.8±12.2 64.1±16.9 <0.0001 <0.0001
Non– HDL- C, mg/dL 106.1±32.6 126.7±42.5 <0.0001 <0.0001
Triglycerides, mg/dL 95.5 (71.5– 147.0) 102 (70– 148) 0.66 0.66
Results are presented as mean±SD, median (interquartile range), or frequency (percentage). Data on low- density lipoprotein cholesterol (LDL- C) were missing 
for 4 participants (n=3 Fontan and n=1 control) because of triglyceride level >400 mg/dL. Adjusted P values reflect linear regression adjusted for age, sex, and 
body mass index (analyses for these 3 variables adjust for the other 2).
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; HDL- C, high- density lipoprotein cholesterol; hs- CRP, high- sensitivity C- reactive 
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DISCUSSION
These data demonstrate that: (1) patients with a Fontan 
circulation have lower total cholesterol, HDL- C, LDL- C, 
and non– HDL- C compared with controls; (2) HDL- C is 
affected by the same key drivers in patients with a Fontan 
circulation as is seen in the general population (lower 
HDL- C is associated with male sex, higher BMI, and 
higher hs- CRP); and (3) lower HDL- C is independently 
associated with adverse outcomes in patients with a 
Fontan circulation. Prior studies have suggested an 
association between hypocholesterolemia and Fontan 
circulation, which we have confirmed with a prospec-
tively enrolled cohort of participants with Fontan and 
controls.5,6 In addition, we describe the relationship 
between lipid levels and clinical outcomes in patients 
with a Fontan circulation. While the effect size of low 
HDL- C is too small to be used alone to predict which 
patients are at increased risk of morbidity or mortal-
ity, HDL- C has the potential to be used in combination 
with other biomarkers and clinical factors to aid in risk 
stratifying this high- risk population.
The Fontan procedure has been successful in al-
lowing patients with single ventricles to live to adult-
hood. However, after a "honeymoon period" during 
early childhood, there is an increasing incidence of 
complications in adolescence and adulthood, with 
60% of patients experiencing serious morbidities by 
age 40.12,13 While overt signs of worsening cardiac 
function occasionally occur, many adult patients with 
a Fontan have preserved ventricular systolic function 
with stable valvular function, making predictions about 
who will experience cardiac complications challenging. 
Many studies have attempted to identify circulating bio-
markers that may aid in determining which patients are 
at increased risk of adverse outcomes.2- 4,14 The current 
study has identified HDL- C as an additional biomarker 
that is independently associated with adverse Fontan 
outcomes. HDL- C has the benefit of being inexpen-
sive and frequently obtained in clinical care allowing 
for easy adaptation into the routine screening of adults 
with a Fontan.
The potential causes of hypocholesterolemia in 
patients with Fontan and the association of HDL- C 
with worse outcomes deserves further discussion. 
Atherosclerosis is unlikely to play a role in these find-
ings considering the young age and the low prevalence 
of coronary artery disease in patients with cyanotic 
heart disease even after repair resulting in resolution 
of hypoxemia.15 Some possible explanations for these 
findings could include low levels of physical activity, 
chronic inflammation, or liver dysfunction. The asso-
ciations between low HDL- C and a sedentary lifestyle 
are well established,16,17 and clinical trials have demon-
strated that increased physical activity can lead to 
increased HDL- C.18 However, low HDL- C in the sed-
entary general population is usually associated with 
elevated triglycerides.19 In distinction, triglyceride levels 
in the Fontan cohort did not differ from those in con-
trols. Additionally, lower physical activity is unlikely to 
be the sole driver of the observed pattern of lower total 
cholesterol, LDL- C, and HDL- C with no difference in 
triglycerides compared with controls.
Fontan hypocholesterolemia could also be re-
lated to chronic low- level inflammation. Chronic 
Table 2. Baseline Characteristics of the Fontan Cohort
Patients With Fontan (n=164)
Age, y 27.2 (22.8– 34.4)
Age at Fontan, y 3.8 (2.5– 8.3)
Fontan duration, y 23.1±5.6
Cardiac diagnosis, n (%)
Tricuspid atresia 43 (26)
Double inlet left ventricle 37 (22)
Hypoplastic left heart 25 (15)
Double- outlet right ventricle 19 (12)
Unbalanced AVSD 6 (4)




Left ventricle 54 (33)
Right ventricle 108 (66)
Unknown/indeterminate 2 (1)
Fontan type
Lateral tunnel 100 (61)
Atriopulmonary 33 (20)





β- Blocker 37 (23)
Digoxin 47 (29)




Current tobacco smoker 5 (3)
Diabetes mellitus 5 (3)
Hepatitis B infection (63/164 
tested)
0
Hepatitis C infection (65/164 
tested)
2 (3)
History of PLE 8 (5)
Results are presented as mean±SD, median (interquartile range), or 
frequency (percentage).
ACEI indicates angiotensin- converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; AVSD, atrioventricular septal defect; MRA, 
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inflammatory conditions are known to be associated 
with low HDL- C,20,21 and the degree of elevation of 
inflammatory markers correlates inversely with HDL- 
C.22 At least a third of patients with a Fontan have 
elevated markers of systemic inflammation.23– 25 Our 
present study found an inverse relationship between 
hs- CRP and HDL- C levels. The relationship between 
low HDL- C and adverse outcomes was attenuated 
after accounting for the contribution of hs- CRP. 
Therefore, HDL- C may be a marker of chronic low- 
level inflammation.
Liver dysfunction secondary to FALD could also 
underlie the observed findings. The Fontan circulation 
combines chronic elevation of venous pressure and low 
cardiac output. These hemodynamic derangements 
likely cause FALD, a poorly understood form of liver 
disease characterized by heterogeneous fibrosis, por-
tal hypertension, and eventual cirrhosis.26 Liver fibrosis 
is ubiquitous in adult patients with a Fontan circula-
tion; however, methods to discern different degrees 
of FALD have not been identified.27 The liver plays a 
key role in lipid metabolism, and lipoprotein deficien-
cies are common among patients with chronic liver 
disease.28 In diverse causes of chronic liver disease, 
hypocholesterolemia is inversely related to the severity 
of liver disease and declining lipid levels are indicative 
of liver disease progression.29- 32 One study of patients 
with decompensated cirrhosis reported that a combi-
nation of elevated MELD (Model for End- stage Liver 
Disease) score and low cholesterol was able to more 
accurately discriminate 1- year mortality than the MELD 
score alone.33 Another study of cirrhotic patients listed 
for liver transplant showed that HDL- C levels represent 
the best predictor of survival, and HDL- C <30  mg/
dL was associated with a 3.4- fold higher hazard for 
death.8
Furthermore, some data suggest that hypocho-
lesterolemia may directly contribute to complications 
seen in cirrhosis. Lipoproteins play a crucial role in the 
inactivation of circulating endotoxin; therefore, hypo-
cholesterolemia may contribute to the increased risk 
of infections seen with cirrhosis.7 This study was not 
Figure 1. Distribution of lipids for patients with a Fontan circulation and control patients.
Values for each participant are plotted for (A) triglycerides, (B) total cholesterol, (C) high- density lipoprotein cholesterol (HDL- C), (D) 
low- density lipoprotein cholesterol (LDL- C), and (E) non– high- density lipoprotein cholesterol (non– HDL- C). The thick middle lines 
indicate median values, and error bars represent the 25th to 75th percentiles.
Figure 2. Associations between high- density lipoprotein cholesterol (HDL- C) and body mass index (BMI; A) and HDL- C and log 
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designed to ascertain whether hypocholesterolemia is 
secondary to liver dysfunction. We identified a correla-
tion between hypocholesterolemia and both alanine 
aminotransferase and albumin, however, other as-
sessments of liver disease severity including MELD- XI 
and VAST scores did not correlate with lipid levels. The 
lack of a gold standard for determining stages of FALD 
serves as an obstacle to understanding the relation-
ship between lipid levels and FALD. As FALD becomes 
better understood, further investigations may be able 
to identify whether HDL- C could be useful in discrimi-
nating degrees of FALD.
There are several limitations to our current study. 
Patients with a Fontan may be taking several cardiac 
medications that may affect lipid levels. However, there 
were only 4 patients taking statin medications, which 
have modest effects on HDL- C, and no patients taking 
nonstatin lipid- lowering medications. Many were also 
taking β- blockers, which may also alter serum lipid 
levels. It is, however, doubtful that medication use ac-
counts for the marked differences observed in HDL- C. 
Another limitation is that low HDL- C is known to be 
associated with lower physical activity. Adequately 
capturing the type, duration, and frequency of physi-
cal activity is not possible with medical record review, 
and lower physical activity is likely causally associated 
with worse Fontan outcomes. Last, patients were not 
fasting at the time of the blood draws, which may limit 
interpretation of the triglyceride levels, and HDL- C level 
does not necessarily indicate HDL function.
CONCLUSIONS
Patients with a Fontan circulation have lower total cho-
lesterol, HDL- C, and LDL- C compared with healthy 
volunteer controls, and lower HDL- C is indepen-
dently associated with adverse outcomes. Further 
Table 4. Clinical and Laboratory Variables of the Fontan Cohort by HDL- C Tertile
HDL- C Tertile
Lowest (<36 mg/dL) Middle (36– 47 mg/dL) Highest (>47 mg/dL) P Value
Age, y 28.7 (23.5– 32.6) 27.6 (22.2– 35.5) 27.3 (22.6– 38.3) 0.13
Time since Fontan, y 23.1 (19.6– 26.9) 22.2 (18.8– 25.7) 23.1 (19.9– 26.8) 0.79
Female 13 (25) 25 (42) 31 (58) 0.002*
Body mass index, kg/m2 27.4±5.1 24.5±3.9 23.9±4.0 <0.0001*
Creatinine, mg/dL 0.9±0.2 0.9±0.2 0.9±0.2 0.73
AST, U/L (n=163) 28.2±10.2 25.9±9.8 25.8±6.6 0.18
ALT, U/L (n=163) 32.4±14.9 26.2±11.5 24.9±8.5 0.001*
Alkaline phosphatase, U/L (n=153) 86.5±28.7 86.1±25.2 91.5±36.7 0.41
Total bilirubin, mg/dL (n=163) 1.0±1.0 1.2±1.1 0.9±0.5 0.47
Albumin, mg/dL 4.6±0.7 4.6±0.4 4.7±0.3 0.11
MELD- XI score (n=163) 9.4 (9.4– 10.8) 9.4 (9.4– 11.5) 9.4 (9.4– 10.8) 0.59
Total cholesterol, mg/dL 153±33 143±29 152±27 0.87
Triglycerides, mg/dL 124 (85– 184) 96 (71– 140) 81 (62– 103) <0.0001*
Log triglycerides 4.9±0.6 4.6±0.5 4.4±0.4 <0.0001*
LDL- C, mg/dL 91.4±24.3 80.2±25.1 76.5±25.0 0.003*
Non– HDL- C, mg/dL 122.3±34.1 102.2±29.7 94.7±28.2 <0.0001*
Peak VO2, % predicted (n=131) 56.9±15.6 59.5±13.5 63±14.1 0.049*
hs- CRP, mg/dL (n=163) 1.9 (0.9– 5.2) 1.3 (0.8– 2.5) 1.0 (0.6– 2.0) 0.002*
Log hs- CRP 0.8±1.2 0.3±1 0.17±0.96 0.002*
Oxygen saturation, % (n=146) 95 (92– 96) 93 (91– 95) 95 (92– 96) 0.36
Hemoglobin, g/dL 15.7±1.7 15.3±1.9 15.0±1.9 0.055
Platelets, K/µL (n=157) 183±59 172±55 188±51 0.68
NT- proBNP, pg/mL (n=131) 134 (64– 261) 120 (66– 323) 173 (82– 331) 0.37
VAST score (n=160) 1 (0– 2) 1 (0– 2) 0 (0– 2) 0.16
Results are presented as mean±SD, median (interquartile range), or frequency (percentage). ALT indicates alanine aminotransferase; AST, aspartate 
aminotransferase; HDL- C, high- density lipoprotein cholesterol; hs- CRP, high- sensitivity C- reactive protein; LDL- C, low- density lipoprotein cholesterol; MELD- XI, 
model for End- stage Liver Disease score excluding INR; non– HDL- C, non– high- density lipoprotein cholesterol; NT- proBNP, N- terminal pro- B- type natriuretic 
peptide; VO2, peak oxygen consumption (as measured during exercise testing); and VAST, imaging features of portal hypertension: 1 point each for varices, 
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investigation is needed to determine the cause of de-
creased lipid levels and whether HDL- C could be a 
marker of more advanced liver disease in patients with 
a Fontan circulation.
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Table S1. Clinical and Laboratory Variables of the Fontan cohort, by composite outcome. 




Yes (n=56) No (n=108) P value 
Adjusted 
P value* 
Age (years) 32.6 (23.9-42.6) 25.2 (22.6-30.6) 0.001 0.13 
Female 26 (46%) 43 (40%) 0.50 0.42 
Body mass index (kg/m2) 25.3 ± 4.5 25.1 ± 4.6 0.79 0.13 
Creatinine (mg/dL) 0.9 ± 0.2 0.9 ± 0.2 0.91 0.07 
AST (U/L)  25.9 ± 8.8 27.2 ± 9.2 0.48 0.63 
ALT (U/L)  26.7 ± 13.2 28.3 ± 11.7 0.41 0.76 
Alkaline phosphatase (U/L)  92.0 ± 30.62 86.2 ± 30.5 0.27 0.67 
Bilirubin, total (mg/dL)  0.9 ± 1.0 1.1 ± 0.9 0.34 0.75 
Albumin (mg/dL)  4.5 ± 0.7 4.7 ± 0.3 0.002 0.07 
MELD-XI score (n=163) 9.4 (9.4-10.8) 9.4 (9.4-11.2) 0.60 0.17 
Total cholesterol (mg/dL) 151 ± 30 148 ± 30 0.62 0.68 
LDL cholesterol (mg/dL) 86.1 ± 25.5 80.6 ± 25.4 0.19 0.07 
HDL cholesterol (mg/dL) 40.2 ± 10.7 44.2 ± 12.7 0.04 0.02 
Triglycerides (mg/dL) 124 (77-133) 116 (71-149) 0.61 0.83 
Log Triglycerides 4.7 ± 0.5 4.6 ± 0.5 0.72 0.94 
Log hsCRP  0.8 ± 1.1 0.2 ± 1.0 <0.001 <0.001 
Hemoglobin (gm/dL)  14.8 ± 1.6 15.7 ± 1.9 0.004 0.42 
Platelets (K/mcl)  190 ± 63 176 ± 50 0.13 0.053 
Log NT-proBNP 5.4 ± 1.1 4.7 ± 1.2 0.002 0.04 
VAST score  1 (0-2) 0 (0-1) <0.001 0.004 
Peak VO2 (% predicted) (n=131) 56.1 ± 16.1 61.6 ± 13.3 0.004 0.07 
NYHA 1 (1-2) 1 (1-2) 0.04 0.004 
ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, hsCRP: high-sensitivity C-
reactive protein, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, MELD-XI: Model 
for End-stage Liver Disease (MELD) score excluding INR, NT-proBNP: N-terminal pro-B-type 
natriuretic peptide, VO2: peak oxygen consumption as measured during exercise testing, VAST: 
features of portal hypertension (1 point each for Varices, Ascites, Splenomegaly, or 
Thrombocytopenia). Results are presented as mean ± standard deviation, median (IQR), or 
frequency (%). 
*Adjusted P values reflect Cox proportional hazards model, with the variable listed in the table 
adjusted for age, sex, VAST score, and NYHA functional class 1 vs 2+. Platelet count was not 
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